HOME >> BIOLOGY >> NEWS
The Parkinson's Institute to conduct Phase III Clinical Trial of creatine for Parkinson's disease

The Parkinsons Institute will participate in a large-scale national clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease (PD). While creatine is not an approved therapy for PD or any other condition, it is widely thought to improve exercise performance. The potential benefit of creatine for PD was identified by Parkinsons researchers through a new rapid method for screening potential compounds. The trial, which begins today, is sponsored by the National Institutes of Health (NIH).

The double-blind, placebo-controlled, phase III study is one of the largest PD clinical trials to date. The Parkinsons Institute is one of 51 medical centers in the United States and Canada that will be recruiting patients as part of an effort to enroll 1720 people with early-stage PD.

"This study is an important step. We are pleased to have so many sites participating in this study, which may help us move more quickly toward developing a therapy that could change the course of this devastating disease," says Elias A. Zerhouni, M.D., director of the NIH. "The goal is to improve the quality of life for people with Parkinson's for a longer period of time than is possible with existing therapies." Currently there is no treatment that has been shown to slow the progression of PD.

The trial is the first large study in a series of NIH-sponsored clinical trials called NET-PD (NIH Exploratory Trials in Parkinson's Disease). The Parkinsons Institute has been affiliated with the program since 2002. The NIH has organized this large network of sites to allow researchers to work with PD patients over a long period of time, with a goal of finding effective and lasting treatments. NET-PD builds on a developmental research process from laboratory research to pilot studies in a select group of patients to the definitive phase III trial of effectiveness in people with PD.

"This study is an example
'"/>

Contact: Alicia Swanson
alicia.swanson@comcast.net
408-836-7170
The Parkinson's Institute
22-Mar-2007


Page: 1 2 3

Related biology news :

1. Scientists identify 2 distinct Parkinsons networks
2. Tracing Parkinsons lethal mechanism
3. Lancet study shows gene therapy for Parkinsons disease is safe and some patients benefit
4. Gene therapy study shows safety and statistically significant improvement in Parkinsons disease
5. PINK1 protects from Parkinsons
6. Parkinsons protein protects neurons from stress induced cell death
7. UCLA researchers discover link between Parkinsons and narcolepsy
8. Alzheimers, Parkinsons, type 2 diabetes similar at molecular level
9. Nanotechnology offers hope for treating spinal cord injuries, diabetes and Parkinsons disease
10. New studies link the environment to Parkinsons disease
11. NIH announces phase III clinical trial of creatine for Parkinsons disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/6/2019)... ... 2019 , ... Rigaku Corporation , a global leader ... & Microanalysis 2019 Meeting ( M&M 2019 ), taking place August 4 - ... & Microanalysis Meeting, organized by the Microscopy Society of America, is the world’s ...
(Date:8/1/2019)... ... August 01, 2019 , ... John R. Freeman, CPA, has joined BioLabs ... and president of BioLabs, which provides premier co-working spaces for life science startups in ... ability to forecast and manage growth,” says Fruehauf. “BioLabs has expanded to 10 locations ...
(Date:7/26/2019)... LOS ANGELES (PRWEB) , ... July 26, 2019 ... ... pleased to announce an exclusive interview with Helius Medical Technologies CEO Phil Deschamps ... or trauma. , Helius Medical Technologies is a neurotech company in ...
Breaking Biology News(10 mins):
(Date:8/8/2019)... ... August 08, 2019 , ... ... for sales and service organizations, today announced that the company’s Studio Intelligent ... for the IVA market . Inference will officially accept the award at Frost ...
(Date:8/6/2019)... ... August 05, 2019 , ... ... been recognized as a distinguished leader by PharmaVOICE magazine, earning him a prestigious ... in the magazine’s July/August special issue. , As the executive vice president of ...
(Date:7/26/2019)... ... , ... LeadingBiotech , an exclusive event series bringing ... Boston BD conference to be held on September 10, 2019, at the ... event provides an opportunity for attendees to leverage insight from real-life business development ...
(Date:7/17/2019)... ... , ... CRISPR is often thought of as “molecular scissors” used for precision ... edited, but Yiping Qi, assistant professor in Plant Science & Landscape Architecture at the ... in Nature Plants. In this comprehensive review, Qi and coauthors in his lab explore ...
Breaking Biology Technology:
Cached News: